• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Quality adjusted survival analysis with repeated quality of life measures.

作者信息

Glasziou P P, Cole B F, Gelber R D, Hilden J, Simes R J

机构信息

Department of Social & Preventive Medicine, University of Queensland Medical School, Herston, Australia.

出版信息

Stat Med. 1998 Jun 15;17(11):1215-29. doi: 10.1002/(sici)1097-0258(19980615)17:11<1215::aid-sim844>3.0.co;2-y.

DOI:10.1002/(sici)1097-0258(19980615)17:11<1215::aid-sim844>3.0.co;2-y
PMID:9670411
Abstract

One way of examining trade-offs between quantity and quality of life (QOL) is to combine them into a single measure such as quality-adjusted life year (QALY). If censoring occurs, then estimation presents some difficulties. One approach, known as Q-TWiST, is to define a series of health states, use a 'partitioned' survival analysis to calculate the average time in each state, and then weight each state according to its quality of life to calculate QALYs. Such health-state models, however, are unhelpful when the transitions between health states are unclear or if they do not adequately reflect variations in quality of life. We therefore examine an alternative analysis to be used when repeated measures of quality of life are available from individual patients in a clinical trial. The method proceeds by separating quality of life and survival, that is, dQALY/dt = S(t)Q(t), where S(t) is the survival curve, estimated from the standard Kaplan-Meier method, and Q(t) is the quality of life function, derived from individual repeated measures of quality of life. We derive single health-state (QALY) and multiple health-state (Q-TWiST) models and illustrate the approach by comparing different durations of adjuvant chemotherapy for breast cancer.

摘要

相似文献

1
Quality adjusted survival analysis with repeated quality of life measures.
Stat Med. 1998 Jun 15;17(11):1215-29. doi: 10.1002/(sici)1097-0258(19980615)17:11<1215::aid-sim844>3.0.co;2-y.
2
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival.
Cancer J Sci Am. 1995 Jul-Aug;1(2):114-21.
3
Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.环磷酰胺、表柔比星、氟尿嘧啶与环磷酰胺、甲氨蝶呤、氟尿嘧啶治疗绝经前淋巴结阳性乳腺癌的Q-TWiST分析
Pharmacoeconomics. 2005;23(1):69-75. doi: 10.2165/00019053-200523010-00006.
4
A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group.
Stat Med. 1995 Aug 30;14(16):1771-84. doi: 10.1002/sim.4780141606.
5
Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.
Eur J Clin Pharmacol. 1997;53(3-4):281-2. doi: 10.1007/s002280050378.
6
Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.生存估计的参数外推法及其在治疗生活质量评估中的应用。国际乳腺癌研究组。
Control Clin Trials. 1993 Dec;14(6):485-99. doi: 10.1016/0197-2456(93)90029-d.
7
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松辅助化疗与单药左旋苯丙氨酸氮芥治疗可手术乳腺癌且腋窝淋巴结阳性患者的比较:西南肿瘤协作组20年研究结果
Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982.
8
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.接受拉帕替尼联合紫杉醇作为转移性乳腺癌一线治疗的患者的生活质量和质量调整生存(Q-TWiST)。
Curr Med Res Opin. 2010 Apr;26(4):767-75. doi: 10.1185/03007991003590860.
9
Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.日本高危早期乳腺癌患者强化化疗联合预防性粒细胞集落刺激因子的经济学评价。
Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.
10
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.辅助化疗联合他莫昔芬与单纯他莫昔芬治疗绝经后乳腺癌的疗效比较:质量调整生存的荟萃分析
Lancet. 1996 Apr 20;347(9008):1066-71. doi: 10.1016/s0140-6736(96)90277-9.

引用本文的文献

1
Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.随机临床试验的健康效用生存分析:扩展与统计特性
Stat Med. 2025 Aug;44(18-19):e70215. doi: 10.1002/sim.70215.
2
Predicting EQ-5D-3L utility values from clinical data in a prospective cohort of kidney transplant recipients.在前瞻性肾移植受者队列中根据临床数据预测EQ-5D-3L效用值。
Eur J Health Econ. 2025 Jun 11. doi: 10.1007/s10198-025-01802-6.
3
Implementation and prospective evaluation of the Country Heart Attack Prevention model of care to improve attendance and completion of cardiac rehabilitation for patients with cardiovascular diseases living in rural Australia: a study protocol.
实施和前瞻性评估澳大利亚农村地区心血管疾病患者的“乡村心脏病发作预防护理模式”,以改善其心脏康复的参与度和完成率:一项研究方案。
BMJ Open. 2022 Feb 16;12(2):e054558. doi: 10.1136/bmjopen-2021-054558.
4
Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.达可替尼的模型化经济分析——中国治疗表皮生长因子受体(EGFR)突变阳性非小细胞肺癌患者的成本效益分析
Front Oncol. 2021 Dec 14;11:564234. doi: 10.3389/fonc.2021.564234. eCollection 2021.
5
Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.冠状动脉旁路移植术联合二尖瓣修复术与单纯冠状动脉旁路移植术治疗中度缺血性二尖瓣反流的成本效益比较。
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2230-2240.e15. doi: 10.1016/j.jtcvs.2019.06.040. Epub 2019 Jul 2.
6
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.奥拉帕利作为铂敏感复发性卵巢癌患者的维持治疗药物。
Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
7
Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network.二尖瓣修复术与置换术治疗重度缺血性二尖瓣反流的成本效益:心胸外科手术试验网络的一项随机临床试验
Circ Cardiovasc Qual Outcomes. 2018 Nov 14;11(11):e004466. doi: 10.1161/CIRCOUTCOMES.117.004466.
8
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.在化疗后接受奥拉帕利维持治疗的铂敏感复发性卵巢癌且存在 BRCA1/2 突变患者中的健康相关生活质量和以患者为中心的结局(SOLO2/ENGOT Ov-21):一项安慰剂对照、III 期随机试验。
Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.
9
Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.在存在终末事件的情况下使用标记过程进行非参数效益-风险评估。
J Am Stat Assoc. 2017;112(518):826-836. doi: 10.1080/01621459.2016.1180988. Epub 2017 Apr 12.
10
Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.依维莫司治疗加拿大胃肠道或肺源性晚期神经内分泌肿瘤的成本效益。
Curr Oncol. 2018 Feb;25(1):32-40. doi: 10.3747/co.25.3532. Epub 2018 Feb 28.